KYMERA THERAPEUTICS INC. - COMMON STOCK

Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

02 يونيو 2021 16:00:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase

26 مايو 2021 09:00:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

10 مايو 2021 09:00:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update

06 مايو 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology

05 مايو 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics to Present at Upcoming May Investor Conferences

04 مايو 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

03 مايو 2021 16:00:40 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Presents Positive Late-Breaking Data from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology 2021 Annual Meeting

03 مايو 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company

19 أبريل 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021

10 أبريل 2021 08:30:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual Meeting

09 أبريل 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors

16 مارس 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

11 مارس 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases

02 مارس 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics to Present at Upcoming March Investor Conferences

25 فبراير 2021 07:00:03 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics to Present at Upcoming February Investor Conferences

04 فبراير 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions

03 فبراير 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company

12 يناير 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

05 يناير 2021 16:01:00 بحسب Nasdaq GlobeNewswire